TY - JOUR
T1 - Hesperidin-3′- O -methylether is more potent than hesperidin in phosphodiesterase inhibition and suppression of ovalbumin-induced airway hyperresponsiveness
AU - Yang, You Lan
AU - Hsu, Hsin Te
AU - Wang, Kuo Hsien
AU - Wang, Chao Sian
AU - Chen, Chien Ming
AU - Ko, Wun-Chang
PY - 2012
Y1 - 2012
N2 - Hesperidin is present in the traditional Chinese medicine, "Chen Pi," and recently was reported to have anti-inflammatory effects. Therefore, we were interested in comparing the effects of hesperidin and hesperidin-3′-O-methylether on phosphodiesterase inhibition and airway hyperresponsiveness (AHR) in a murine model of asthma. In the present results, hesperidin-3′-O-methylether, but not hesperidin, at 30 mol/kg (p.o.) significantly attenuated the enhanced pause (P enh) value, suppressed the increases in numbers of total inflammatory cells, macrophages, lymphocytes, neutrophils, and eosinophils, suppressed total and OVA-specific immunoglobulin (Ig)E levels in the serum and BALF, and enhanced the level of total IgG 2 a in the serum of sensitized and challenged mice, suggesting that hesperidin-3′-O-methylether is more potent than hesperidin in suppression of AHR and immunoregulation. The different potency between them may be due to their aglycons, because these two flavanone glycosides should be hydrolyzed by β-glucosidase after oral administration. Neither influenced xylazine/ketamine-induced anesthesia, suggesting that they may have few or no adverse effects, such as nausea, vomiting, and gastric hypersecretion. In conclusion, hesperidin-3′-O-methylether is more potent in phosphodiesterase inhibition and suppression of AHR and has higher therapeutic (PDE 4 H / PDE 4 L) ratio than hesperidin. Thus, hesperidin-3′-O- methylether may have more potential for use in treating allergic asthma and chronic obstructive pulmonary disease.
AB - Hesperidin is present in the traditional Chinese medicine, "Chen Pi," and recently was reported to have anti-inflammatory effects. Therefore, we were interested in comparing the effects of hesperidin and hesperidin-3′-O-methylether on phosphodiesterase inhibition and airway hyperresponsiveness (AHR) in a murine model of asthma. In the present results, hesperidin-3′-O-methylether, but not hesperidin, at 30 mol/kg (p.o.) significantly attenuated the enhanced pause (P enh) value, suppressed the increases in numbers of total inflammatory cells, macrophages, lymphocytes, neutrophils, and eosinophils, suppressed total and OVA-specific immunoglobulin (Ig)E levels in the serum and BALF, and enhanced the level of total IgG 2 a in the serum of sensitized and challenged mice, suggesting that hesperidin-3′-O-methylether is more potent than hesperidin in suppression of AHR and immunoregulation. The different potency between them may be due to their aglycons, because these two flavanone glycosides should be hydrolyzed by β-glucosidase after oral administration. Neither influenced xylazine/ketamine-induced anesthesia, suggesting that they may have few or no adverse effects, such as nausea, vomiting, and gastric hypersecretion. In conclusion, hesperidin-3′-O-methylether is more potent in phosphodiesterase inhibition and suppression of AHR and has higher therapeutic (PDE 4 H / PDE 4 L) ratio than hesperidin. Thus, hesperidin-3′-O- methylether may have more potential for use in treating allergic asthma and chronic obstructive pulmonary disease.
UR - http://www.scopus.com/inward/record.url?scp=84874866580&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84874866580&partnerID=8YFLogxK
U2 - 10.1155/2012/908562
DO - 10.1155/2012/908562
M3 - Article
C2 - 23082087
AN - SCOPUS:84874866580
SN - 1741-427X
VL - 2012
JO - Evidence-based Complementary and Alternative Medicine
JF - Evidence-based Complementary and Alternative Medicine
M1 - 908562
ER -